GlassScriptPhysician profile
Douglas Nowacki
NPI 1518302660
$17,400.88
in general payments reported to CMS, 2019-2025
29 companies · $1,137 in 2025
The $1,137 reported for 2025 was less than what a typical Orthopaedic Surgery of The Spine provider received nationally (typical 2025 total: $2,116).
See the full distribution for Orthopaedic Surgery of the Spine
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,850 · 2020: $609 · 2021: $1,024 · 2022: $2,287 · 2023: $2,791 · 2024: $1,704 · 2025: $1,137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,509 · Travel and Lodging: $1,084 · Entertainment: $39.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,509.02 |
| Travel and Lodging | $1,083.60 |
| Entertainment | $39.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $4,258.68 | 2019-2025 | Spinemap, Mako, Monterey Al |
| Medtronic, INC. | $3,707.02 | 2021-2025 | Mazor X System, T2 Stratosphere Expandable Corpectomy System, Space-D System 5.5/6.0 Voyager Instrument Set |
| Nuvasive, INC. | $3,058.83 | 2019-2022 | |
| Medtronic USA, INC. | $1,872.68 | 2019 | |
| Globus Medical, INC. | $1,146.14 | 2023-2025 | Excelsiusgps Robotic Navigation System, Excelsius Gps, Sable |
| Providence Medical Technology, INC. | $878.78 | 2023-2025 | |
| Alphatec Spine, INC | $638.31 | 2022-2025 | Invictus Mis, Other - Miscellaneous, Identiti |
| Depuy Synthes Sales INC. | $432.82 | 2019-2020 | |
| Djo, LLC | $238.58 | 2023-2024 | Cmf |
| Boston Scientific Corporation | $172.86 | 2020-2024 | |
| Augmedics INC. | $142.88 | 2024-2025 | Xvision |
| Nevro Corp. | $114.30 | 2019 | |
| Biotronik Nro, INC. | $109.38 | 2024 | Prospera |
| Spinal Elements, INC. | $106.89 | 2024 | |
| Curonix LLC | $76.27 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanara Medtech INC. | $69.43 | 2025 | Celleraterx |
| Integrity Implants INC. | $46.04 | 2022 | |
| Si-Bone, INC. | $43.87 | 2021-2022 | |
| Saluda Medical Americas, INC. | $41.30 | 2023 | Evoke Scs |
| Integra Lifesciences Corporation | $38.09 | 2024 | Codman Certas, Codman Hakim, Cusa Clarity |
| Abbvie INC. | $34.61 | 2024 | |
| Foundation Fusion Solutions, LLC | $30.87 | 2023-2024 | |
| Acera Surgical, INC. | $29.67 | 2025 | Restrata Wound Matrix |
| Solventum Corporation | $25.04 | 2025 | Prevena |
| Electronic Waveform Lab, INC. | $23.53 | 2024-2025 | |
| Mimedx Group, INC. | $19.75 | 2024 | |
| Smith+Nephew, INC. | $15.91 | 2024 | Collagenase Santyl |
| Highridge Medical LLC | $14.22 | 2024 | Biomet Spinalpak Non-Invasive Spine Fusion Stimulator System |
| Collegium Pharmaceutical, INC. | $14.13 | 2025 | Xtampza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Nowacki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.